This is a story of precision medicines and their value.
The drug is alipogene tiparvovec (aka Glybera). Approved in 2012, it is “a medicine widely heralded as the “first gene therapy” in the Western world” – a treatment to correct DNA.
But when the Berlin physician Elisabeth Steinhagen-Thiessen wanted to give a patient Glybera last fall, it wasn’t so easy. She […]
The current issue of Health Affairs (March 2015; Volume 34, Issue 3) includes six papers under the heading Paying for Value about the value of information, value of procedures, and payment systems.
Alan R. Weil, Editor-in-Chief, comments in the accompanying editorial:
“… there is a long distance between a general call for information and transparency and the positive results that information […]
“One fundamental problem may be a misguided perspective that health care is a binary world in which interventions are either effective or ineffective, appropriate or inappropriate. In truth, there are large gray zones in which an intervention is neither clearly effective nor clearly ineffective — zones where benefits are unknown or uncertain and value may depend on patients’ preferences […]
A new study by colleagues at LSE, Alessandra Ferrario and Panos Kanavos:
Dealing with uncertainty and high prices of new medicines: A comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden, Social Science & Medicine, Volume 124, January 2015, Pages 39-47,
Available at: http://www.sciencedirect.com/science/article/pii/S0277953614007266
A combination of high prices of new patented medicines, […]
A Lancet overview blog post explaining value-based pricing, with some useful references – published 16 August 2013.
http://ukpolicymatters.thelancet.com/value-based-pricing/
This article from Le Monde explains how medicines are priced in Europe.
Comment est fixé le prix d’un médicament
http://www.lemonde.fr/economie/article/2014/09/30/comment-est-fixe-le-prix-d-un-medicament_4497112_3234.html
Especially of relevance the part about really innovative medicines: “pour les produits les plus innovants – une dizaine par an –, autorisés au niveau européen et qui obtiennent une note élevée de la part de la Commission de la transparence, le prix […]
A Perspective paper:
Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY Threshold
by
Peter J. Neumann, Sc.D., Joshua T. Cohen, Ph.D., and Milton C. Weinstein, Ph.D.
New Englangd Journal of Medicine, 2014; 371:796-797
Published August 28, 2014
DOI: 10.1056/NEJMp1405158
http://www.nejm.org/doi/full/10.1056/NEJMp1405158?rss=searchAndBrowse
“For more than two decades, the ratio of $50,000 per quality-adjusted life-year (QALY) gained by using a given health care intervention has played an important […]
Westminster Health Forum Keynote Seminar
Next steps for NICE: integration, medicine pricing and value based assessments
Morning, Thursday, 15th January 2015
Central London
with:
Professor Gillian Leng, Deputy Chief Executive and Director of Health and Social Care, NICE; Paul Catchpole, Director of Value and Access, ABPI; Dr Sunjai Gupta, Consultant and Senior Scientific Advisor, Health and Wellbeing Directorate, Public Health England; Dr Zahid Latif, […]
A paper about value base pricing but also about how a classification embodies value :
“What Is the FDA Going to Think?”: Negotiating Values through Reflective and Strategic Category Work in Microbiome Science
Katherine W. Darling, Angie M. Boyce, Mildred K. Cho, and Pamela L. Sankar
in:
Science, Technology & Human Values, January 2015 40: 71-95,
first published on August 4, 2014 […]
Gallery